Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Cerilliant
Deloitte
Dow
Fish and Richardson
Fuji
Colorcon

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,320,800

« Back to Dashboard

Which drugs does patent 7,320,800 protect, and when does it expire?

Patent 7,320,800 protects ENDOMETRIN and is included in one NDA.

This patent has eleven patent family members in nine countries.
Summary for Patent: 7,320,800
Title:Vaginally administrable progesterone-containing tablets and method for preparing same
Abstract:The present invention provides a method for preparing a tablet for the vaginal administration of progesterone for systemic use. The method comprises first mixing water with micronized progesterone, the total amount of water mixed with said micronized progesterone not exceeding the maximum wetting capacity of the micronized progesterone, drying the wetted, micronized progesterone; mixing the dry micronized progesterone with other pharmaceutically acceptable excipients or diluents; and; forming a tablet by direct compaction of the dry micronized progesterone. Tablets prepared by this method are also provided.
Inventor(s): Jossifoff; Azariah (Ramat Gan, IL)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:11/039,062
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery;

Drugs Protected by US Patent 7,320,800

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ferring ENDOMETRIN progesterone INSERT;VAGINAL 022057-001 Jun 21, 2007 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,320,800

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Israel127129Nov 18, 1998

Non-Orange Book US Patents Family Members for Patent 7,320,800

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,300,664 Vaginally administrable progesterone-containing tablets and method for preparing same ➤ Try a Free Trial
7,393,543 Vaginally administratable progesterone-containing tablets and method for preparing same ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,320,800

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1176200 ➤ Try a Free Trial
Canada 2568823 ➤ Try a Free Trial
Denmark 1131052 ➤ Try a Free Trial
European Patent Office 1131052 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
UBS
Chinese Patent Office
Covington
Chubb
Cantor Fitzgerald
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.